TOPAMAX 100 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

topamax 100 mg

janssen-cilag s.p.a. - italia - topiramatum - compr. film. - 100mg - antiepileptice alte antiepileptice

TOPAMAX 50 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

topamax 50 mg

janssen-cilag s.p.a. - italia - topiramatum - compr. film. - 50mg - antiepileptice alte antiepileptice

TOPAMAX 25 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

topamax 25 mg

janssen-cilag s.p.a. - italia - topiramatum - compr. film. - 25mg - antiepileptice alte antiepileptice

ZALDIAR 37,5 mg/325 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

zaldiar 37,5 mg/325 mg

stada arzneimittel ag - germania - combinatii (tramadolum+paracetamolum) - compr. film. - 37,5mg/325mg - alcaloizi naturali din opiu opioide in combinatie cu analgezice non-opioide

Lonsurf Uniunea Europeană - română - EMA (European Medicines Agency)

lonsurf

les laboratoires servier - trifluridine, tipiracil clorhidrat de - neoplasme colorectale - agenți antineoplazici - colorectal cancerlonsurf is indicated in combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (crc) who have received two prior anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and/or anti-egfr agents. lonsurf is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer (crc) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and anti egfr agentsgastric cancerlonsurf is indicated as monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease.